Kintegral Advisory LLC Sells 1,227 Shares of Humana Inc. (NYSE:HUM)

Kintegral Advisory LLC reduced its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 32.9% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 2,505 shares of the insurance provider's stock after selling 1,227 shares during the period. Kintegral Advisory LLC's holdings in Humana were worth $665,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. LFA Lugano Financial Advisors SA grew its position in Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after purchasing an additional 45 shares during the period. OFI Invest Asset Management acquired a new stake in Humana during the 4th quarter worth about $33,000. Riverview Trust Co acquired a new stake in shares of Humana during the 1st quarter valued at about $34,000. Garde Capital Inc. acquired a new stake in shares of Humana during the 1st quarter valued at about $36,000. Finally, Transce3nd LLC acquired a new stake in shares of Humana during the 4th quarter valued at about $38,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HUM has been the topic of a number of analyst reports. Bank of America dropped their target price on Humana from $320.00 to $260.00 and set a "neutral" rating on the stock in a research report on Tuesday, June 17th. Barclays set a $268.00 target price on Humana and gave the stock an "equal weight" rating in a report on Thursday, June 12th. Guggenheim began coverage on Humana in a report on Wednesday, April 9th. They set a "buy" rating and a $326.00 target price on the stock. Cantor Fitzgerald reiterated a "neutral" rating and issued a $290.00 price objective on shares of Humana in a report on Thursday, May 1st. Finally, Wall Street Zen upgraded Humana from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Sixteen research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $280.76.

Humana Price Performance

Shares of NYSE HUM traded down $3.69 during mid-day trading on Monday, reaching $235.99. 821,657 shares of the company traded hands, compared to its average volume of 1,813,985. Humana Inc. has a fifty-two week low of $212.45 and a fifty-two week high of $406.46. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.91 and a quick ratio of 1.91. The firm has a market cap of $28.48 billion, a PE ratio of 16.69, a price-to-earnings-growth ratio of 1.81 and a beta of 0.44. The stock has a fifty day simple moving average of $240.29 and a 200-day simple moving average of $259.02.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share for the quarter, topping analysts' consensus estimates of $10.07 by $1.51. Humana had a net margin of 1.42% and a return on equity of 14.47%. The firm had revenue of $32.11 billion during the quarter, compared to analysts' expectations of $32 billion. During the same period last year, the firm posted $7.23 earnings per share. The firm's revenue for the quarter was up 8.4% compared to the same quarter last year. Equities research analysts anticipate that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.50%. The ex-dividend date is Friday, June 27th. Humana's dividend payout ratio (DPR) is currently 25.04%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.